ArticleHeliyon2024
Dextran sulfate inhibits proliferation and metastasis of human gastric cancer cells via miR-34c-5p.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diagnostic significance of miR-34c-5p in patients with postherpetic neuralgia and its correlation with rehabilitation effect.Journal of neurovirology · 2025Article
- Sustainable and biocompatible hybrid materials-based sulfated polysaccharides for biomedical applications: a review.RSC advances · 2025Review
- Dextran sulfate inhibits the invasion, migration, and programmed death-ligand 1 expression in human gastric cancer cells by affecting the M2 tumor-associated macrophage polarization.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a malignant tumor with a high global mortality rate that is currently difficult to treat. Dextran sulfate (DS), a safe anti-tumor agent, can effectively inhibit the malignant biological behavior of gastric cancer; however, its mechanism of action is not fully understood. Therefore, this study aimed at elucidate the potential mechanisms of action. Methods: In this study we used DS to intervene in lentivirus-transfected gastric cancer cells to observe the effect of DS on miR-34c-5p. RT-qPCR, CCK-8, clone formation assay, wound healing assay, transwell assay and western blot were used to examine whether DS affects the proliferation and metastasis of gastric cancer cells via miR-34c-5p. The results were validated using in vivo experiments. Results: Our data confirmed that DS up-regulated miR-34c-5p expression in human gastric cancer cells. Moreover, DS intervention enhanced the inhibitory effect of miR-34c-5p over-expression on the proliferation, invasion, and migration of gastric cancer cells, and partially reversed the promotive effect of miR-34c-5p on the proliferation, invasion, and migration of gastric cancer cells. In addition, DS could affect the activation of the MAP2K1/ERK signaling pathway through the up-regulation of miR-34c-5p, thereby inhibiting the malignant biological behavior of gastric cancer. Finally, it was demonstrated that DS could also inhibit the expression of MAP2K1 in vivo, which in turn inhibits the activation of the ERK signaling pathway to exert anti-cancer effects. Conclusion: DS may inhibit the proliferation and metastasis of gastric cancer cells by regulating miR-34c-5p, which may be a new option for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.